Patents Examined by Sharon X Wen
  • Patent number: 11180569
    Abstract: The present invention relates to a CD20 binding antibody which is capable of depleting B cells, and a BLyS binding antibody which is capable of antagonizing BLyS, as a combination for use in the treatment of an autoimmune disorder. The invention also relates to dosages, duration of treatment and time lapses between administration of the CD20 binding antibody which is capable of depleting B cells, and the BLyS binding antibody which is capable of antagonizing BLyS.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: November 23, 2021
    Inventor: Robert B. Henderson
  • Patent number: 11174323
    Abstract: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are the methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: November 16, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Agnes Lo, Chen Xu, Quan Zhu
  • Patent number: 11167011
    Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Also provided are methods of using the compositions.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: November 9, 2021
    Assignees: Enzo Biochem, Inc., Enzo Theuraputics, Inc.
    Inventors: Joshua Rabbani, Xiaofeng Li, James J. Donegan
  • Patent number: 11161909
    Abstract: The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: November 2, 2021
    Assignee: NOVARTIS AG
    Inventors: Erik Wallström, Marina Savelieva Praz, Algirdas Jonas Kakarieka Weisskopf, Joseph Michael Kahn
  • Patent number: 11155620
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: October 26, 2021
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., The Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Patent number: 11116839
    Abstract: The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: September 14, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: Gary Swergold
  • Patent number: 11104732
    Abstract: The present disclosure relates to a modified cell comprising a polynucleotide encoding a secretable scFv binding SIGLEC-15 and/or encoding a dominant negative form of CD44. In embodiments, the modified cell further comprises an antigen-binding molecule, which for example, is a CAR comprising an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: August 31, 2021
    Inventors: Zhiyuan Cao, Chengfei Pu, Lei Xiao
  • Patent number: 11084854
    Abstract: A protease-resistant neurotrophic peptide is provided. A pharmaceutical composition including the protease-resistant neurotrophic peptide in a pharmaceutically acceptable carrier, in combination with optional adjuvants, stabilizers and/or preservatives, is also provided.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: August 10, 2021
    Assignee: CONSIGLIO NAZIONALE DELLE RICERCHE
    Inventors: Luigi Manni, Marzia Soligo
  • Patent number: 11084884
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: August 10, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
  • Patent number: 11059908
    Abstract: The present invention concerns a method for preparing antigen binding proteins with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: July 13, 2021
    Assignee: AMGEN INC.
    Inventors: Joon Hoi Huh, Riki Stevenson, Pavel Bondarenko, Andrew Nichols, Da Ren, Neeraj Jagdish Agrawal
  • Patent number: 11033619
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: June 15, 2021
    Assignee: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
  • Patent number: 11027015
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: June 8, 2021
    Assignee: Omeros Corporation
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Patent number: 11021540
    Abstract: Antibodies and antigen binding fragments thereof are provided that immunospecifically bind to PD-1, preferably human or mouse PD-1, and induce or promote an immune response that activates immune cell proliferation or activity. Contrary to the existing paradigm that PD-1 exclusively promotes a suppressive immune response, the disclosed antibodies and antigen binding fragments thereof, immunospecifically bind to PD-1 and cause an activating signal to be delivered to the immune cell that activates the immune cell rather than suppressing the immune cell. In one embodiment, the disclosed antibodies and antigen binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen binding fragments thereof to PD-1 on immune cells causes an activating signal to be transmitted into the immune cell, for example a signal that enhances or promotes cytokine production and/or activation of immune cell proliferation.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 1, 2021
    Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
    Inventors: Samir Khleif, Mikayel Mkrtichyan
  • Patent number: 11008381
    Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: May 18, 2021
    Assignee: The Regents of the University of California
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • Patent number: 11008382
    Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: May 18, 2021
    Assignee: The Regents of the University of California
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • Patent number: 10975169
    Abstract: The present disclosure provides methods of treating diabetic retinopathy and ocular inflammatory diseases with anti-ceramide antibodies and antibody fragments.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: April 13, 2021
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventors: Richard Kolesnick, Julia Busik
  • Patent number: 10934524
    Abstract: Provided herein, inter alia, is a method for producing an enriched population of antigen-specific plasma cells. In some embodiments, the method may comprise: (a) obtaining a sample of cells from an animal that has been immunized by an antigen, wherein the sample comprises B cells; (b) enriching for a population of antigen-specific B cells that comprise cell surface antibodies that are specific for the antigen by: i. contacting at least 105 of the cells in said sample, en masse, with the antigen or a portion thereof; and ii. isolating cells that bind to the antigen or portion thereof; and (c) activating the enriched B cells, en masse, in the presence of the antigen or portion thereof, to produce the enriched population of antigen-specific plasma cells.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: March 2, 2021
    Assignee: EPITOMICS, INC.
    Inventors: Luc Adam, Karin Vroom, Liang Xiang, Li Wei, Weimin Zhu
  • Patent number: 10925943
    Abstract: The present invention provides a polypeptide having the formula: St-R1-S1-Q-S2-R2 wherein St is a stalk sequence which, when the polypeptide is expressed at the surface of a target cell, causes the R and Q epitopes to be projected from the cell surface; R1 and R2 are a Rituximab-binding epitopes each having the an amino acid sequence selected from the group consisting of SEQ ID No. 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 or a variant thereof which retains Rituximab-binding activity; S1 and S2 are optional spacer sequences, which may be the same or different; and Q is a QBEnd1O-binding epitope having the amino acid sequence shown as SEQ ID No. 2 or a variant thereof which QBEnd1O-binding activity. The invention also provides a nucleic acid sequence encoding such a polypeptide and uses thereof in adoptive cell transfer.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: February 23, 2021
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Brian Philip
  • Patent number: 10899827
    Abstract: Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that is not present in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 26, 2021
    Assignee: Enzo Biochem, Inc.
    Inventors: Joshua Rabbani, James J. Donegan
  • Patent number: 10865382
    Abstract: The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: December 15, 2020
    Assignee: Innovative Cellular Therapeutics Co., Ltd.
    Inventor: Zhao Wu